GlobeNewswire by notified

Philips Virtual Care Management offers a comprehensive approach to telehealth for patients, providers and payers

Share

March 27, 2023

New solution demonstrates proven results in improving patient engagement, health outcomes, and lowering cost of care while enabling workflow efficiencies

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the debut of Philips Virtual Care Management, a comprehensive portfolio of flexible solutions and services to help health systems, providers, payers and employer groups more meaningfully motivate and deeply connect with patients from virtually anywhere. Philips Virtual Care Management can help reduce pressure on hospital staff by decreasing emergency department visits, as well as reducing the cost of care through better management of chronic disease [1][2].

Every year, chronic condition management represents 90% of healthcare expenditures in the USA [3]. Philips Virtual Care Management’s condition-specific protocols now include diabetes, hypertension, heart disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), as well as gestational programs for diabetes and hypertension. These protocols combine with connected devices and engagement tools on a secure, interoperable cloud-based platform to deliver rich data and actionable insights that enable timely intervention and workflow efficiencies. Licensed clinical professionals offer monitoring and personalized health coaching; and Philips’ expert-led professional services round out the all-inclusive offering to help customers plan, customize, implement, activate and sustain each program.

“Virtual care is paving the way to meaningfully reduce the cost of care through fewer hospitalizations and emergency department visits,” said Nick Wilson, General Manager, Ambulatory Virtual Care at Philips. “Care providers and health systems today are often short on time and resources, accelerating the need to find new ways to gain visibility into patients’ health amid an overwhelming variety of options. For patients, the opportunity to understand and take proactive control of their health can potentially lead to improved outcomes.”

Proven results
Philips’ advanced virtual care program goes beyond traditional remote patient management with scalable solutions and services that help to foster strong patient engagement, empower healthier behaviors, expand access to care, improve outcomes, and lower healthcare costs. Recent studies using Philips Virtual Care Management products and services demonstrated impressive results:

  • Patients saw a 38% average reduction in emergency department visits [1][2]
  • Patients experienced an average HbA1c, or blood glucose, reduction of 3.06% [1][4]
  • Results suggest potential savings of USD 3,086 annual claims per patient or member [1][2]
  • Results suggest fewer 30- and 90-day hospitalizations compared to usual care [1][5]

A comprehensive program with a flexible fit
The highly configurable Philips Virtual Care Management solution offers health systems, providers, payers and employer groups the unique ability to customize their program in a way that shapes and scales with their evolving needs. Philips’ legacy of clinical expertise brings a clearly defined, comprehensive approach to an otherwise fragmented virtual care market by working alongside customers to help them centralize and customize their Philips Virtual Care Management program, optimize workflow and improve outcomes.

On Tuesday, March 28 at 12:00 CT, Nick Wilson will showcase Philips Virtual Care Management on the Tech Talks stage at ViVE 2023 in Nashville during a brief session entitled “Unlock the power of human-centered care, virtually anywhere.” To learn more about Philips’ extensive portfolio of ambulatory virtual care solutions, visit Philips booth #1404 at ViVE or philips.com/virtualcaremanagement.

Philips Virtual Care Management is not currently available outside the USA.

[1] Magee MF, Baker KM, Fernandez SJ, et al. Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes. BMJ Open Diabetes Res Care. 2019;7(1):e000731. Published 2019 Nov 13. doi:10.1136/bmjdrc-2019-000731.
[2] A Diabetes Care Management Program for uncontrolled type 2 diabetes in a predominantly African American population amortized over the study cohort due to reduced risk of all factors hospitalization after 90 days compared to usual care.
[3] Remote patient monitoring system market size, share and trends analysis report by product (vital sign monitors, specialized monitors), by end use, by application, and segment forecasts, 2022-2030. Grand View Research. Accessed November 16, 2022. https://www.grandviewresearch.com/industry-analysis/remote-patient-monitoring-devices-market.
[4] Following a 90-day diabetes care management program in 366 subjects with type 2 diabetes, average baseline HbA1c: 11.2%.
[5] 30 day incidence risk ratio = Intervention (0.21, 95%CI 0.07 to 0.60; p=0.003) vs control (1.14, 95%CI 0.47 to 2.75; p=0.77); between group (p=0.02). 90 day IIR = intervention (0.23, 95%CI 0.11 to 0.50, p<0.001) vs. control (1.58, 95%CI 0.750 to 3.33; p=0.23); between group (P<0.001).

For further information, please contact:

Meredith Amoroso
Philips Global Press Office
Tel.: +1 724 584 8991
E-mail: meredith.amoroso@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Shareholders approve all resolutions on the agendas of Tenaris’s Annual General Meeting and Extraordinary General Meeting of Shareholders1.5.2024 23:10:26 CEST | Press release

LUXEMBOURG, May 01, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced that its annual general meeting of shareholders and its extraordinary general meeting of shareholders, both held on April 30, 2024, approved all resolutions on their agendas. Among other resolutions adopted at the annual general meeting, shareholders acknowledged the Company’s 2023 annual report, containing the consolidated management report and the related management certifications and external auditors’ reports, and the Company’s 2023 annual sustainability report, containing the non-financial statement required by Luxembourg law. The shareholders also approved the consolidated financial statements as of and for the year ended December 31, 2023, and the annual accounts as at December 31, 2023. The annual general meeting also approved an annual dividend of US$0.60 per share (or US$1.20 per ADR), which represents an aggregate sum of approximately US$0.7 billion, and which include

CNH is changing its NYSE ticker symbol to “CNH” on May 201.5.2024 22:30:00 CEST | Press release

Basildon, May 1, 2024 CNH Industrial (NYSE: CNHI) announces that the Company’s common shares listed on the New York Stock Exchange (NYSE) will begin trading under the symbol “CNH” effective Monday, May 20, 2024. This will replace the Company’s current ticker symbol, “CNHI”, marking a return to both our original ticker symbol “CNH” – used until 2013 – and our identity as a leading pureplay provider of equipment, technology and services for agriculture and construction. CNH Industrial N.V. will remain the name of the legal entity. The ticker symbol for the Company’s 3.850% Notes due 2027 will also change from “CNHI 27” to “CNH 27” at the same time. No action is required by the Company's shareholders or bondholders with respect to the ticker symbol changes, as the Company’s common stock and notes will continue to be listed on the NYSE and their CUSIP numbers will remain unchanged. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breakin

Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy Workflow1.5.2024 20:48:50 CEST | Press release

GRENOBLE, France and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in prostate care, announced today the release of new features at the prestigious American Urological Association Annual Meeting in San Antonio, TX. Koelis will be holding live and interactive demos at its booth #951 from May 2nd to May 5th to demonstrate its novel capacity integrating AI-enhanced prostate MRI features into its exclusive Trinity platform. The Koelis Trinity® system enables urologists to perform 3D targeted “fusion biopsy” in prostate cancer. Trinity integrates 3D ultrasound imaging with proprietary MRI-US fusion image guidance that features the Company’s unique prostate motion tracking software (OBT Fusion®). The compact Koelis Trinity® system does not require interfaces with either external ultrasound equipment or external sensors. The versatility of the Trinity platform is enabling Koelis to lead the ongoing paradigm sh

Awilco Drilling Plc: Keppel denied leave to appeal the ruling of the AR2 arbitration tribunal1.5.2024 20:34:14 CEST | Press release

Further to the stock exchange releases of 23 November 2023 and 15 January 2024 from Awilco Drilling PLC ("Awilco Drilling") regarding the termination of the newbuilding contract between Awilco Rig 2 Pte. Ltd. ("AR2") and Keppel FELS Limited ("KFELS") for the construction of a semi-submersible drilling rig, hull number B382. The Company has today received the decision of the High Court refusing Keppel’s application for leave to appeal the award of the AR2 arbitration tribunal. The award is in AR2's favour in an amount of USD 43.0 million plus interest and legal costs. Unless the parties can mutually agree, the tribunal will issue a further award related to interest and costs. We will revert once the award has been received and the amounts of interest and costs have been determined. Aberdeen, 1 May 2024 For further information please contact: Eric Jacobs, CEO of Awilco Drilling PLC Phone: +47 9529 2271 Cathrine Haavind, Investor Relations of Awilco Drilling PLC Phone: +47 9342 8464 Email

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond1.5.2024 18:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder meeting will take place on May 6, 2024, in order to vote on the proposals published on April 23, 2024. Allschwil, Switzerland – May 1, 2024 Idorsia Ltd (SIX: IDIA) today announced that in relation to the bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds), Idorsia has improved the consent fee to 8’000’000 Idorsia shares up from 5’000’000. Other elements of the proposal published on April 23, 2024 such as the (i) amendment to the conversion price to CHF 6.00 (from currently CHF 33.95), (ii) extension of the maturity date by six months to January 17, 2025 and (iii) giving Idorsia the option to call the Bonds at par, in full or in part, at any time upon giving ten trading days' notice, remain unchanged. Bondholders can acc

HiddenA line styled icon from Orion Icon Library.Eye